Q2 Earnings Forecast for SGMT Issued By Wedbush

Key Points

• Wedbush estimates Sagimet Biosciences Inc. will report a Q2 2025 EPS of ($0.56), with a price target of $28.00 and an "Outperform" rating.
• Sagimet recently exceeded analysts' expectations by reporting an EPS of ($0.32) for the latest quarter, surpassing the consensus estimate of ($0.52).
• Seven analysts have given Sagimet Biosciences a "buy" rating, reflecting a positive outlook for the stock with a current consensus price target of $26.57.

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Investment analysts at Wedbush issued their Q2 2025 earnings estimates for shares of Sagimet Biosciences in a note issued to investors on Monday, August 11th. Wedbush analyst Y. Zhong expects that the company will post earnings per share of ($0.56) for the quarter. Wedbush currently has a "Outperform" rating and a $28.00 target price on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.60) per share. Wedbush also issued estimates for Sagimet Biosciences' Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.23) EPS, FY2026 earnings at ($2.34) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($2.19) EPS and FY2029 earnings at ($2.01) EPS.

A number of other equities analysts have also recently commented on SGMT. Jones Trading lifted their price target on shares of Sagimet Biosciences from $15.00 to $27.00 and gave the stock a "buy" rating in a research note on Friday, June 6th. Canaccord Genuity Group assumed coverage on shares of Sagimet Biosciences in a research note on Thursday, July 24th. They set a "buy" rating and a $28.00 price target for the company. Finally, HC Wainwright raised shares of Sagimet Biosciences to a "buy" rating and set a $29.00 price target for the company in a research note on Thursday, August 7th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Sagimet Biosciences currently has an average rating of "Buy" and a consensus target price of $25.67.

Sagimet Biosciences Price Performance

Shares of Sagimet Biosciences stock traded down $0.6950 during trading hours on Thursday, reaching $6.8550. The company's stock had a trading volume of 651,073 shares, compared to its average volume of 1,099,859. The firm has a 50 day moving average price of $8.68 and a 200-day moving average price of $5.31. Sagimet Biosciences has a one year low of $1.73 and a one year high of $11.41. The stock has a market cap of $210.24 million, a P/E ratio of -3.75 and a beta of 3.37.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.20.

Insiders Place Their Bets

In other Sagimet Biosciences news, General Counsel Elizabeth Rozek sold 10,780 shares of the company's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $9.13, for a total value of $98,421.40. Following the transaction, the general counsel directly owned 183,726 shares in the company, valued at $1,677,418.38. This represents a 5.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eduardo Bruno Martins sold 8,277 shares of the stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $9.13, for a total transaction of $75,569.01. Following the transaction, the insider owned 106,936 shares in the company, valued at approximately $976,325.68. This represents a 7.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 84,535 shares of company stock worth $771,805 in the last three months. Corporate insiders own 14.70% of the company's stock.

Hedge Funds Weigh In On Sagimet Biosciences

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in Sagimet Biosciences by 0.6% during the second quarter. Geode Capital Management LLC now owns 265,324 shares of the company's stock valued at $2,023,000 after buying an additional 1,600 shares during the period. American Century Companies Inc. lifted its position in Sagimet Biosciences by 8.9% during the second quarter. American Century Companies Inc. now owns 42,285 shares of the company's stock valued at $322,000 after acquiring an additional 3,454 shares during the last quarter. Abacus Planning Group Inc. lifted its position in Sagimet Biosciences by 14.6% during the second quarter. Abacus Planning Group Inc. now owns 29,968 shares of the company's stock valued at $228,000 after acquiring an additional 3,819 shares during the last quarter. Bank of America Corp DE lifted its position in Sagimet Biosciences by 81.8% during the second quarter. Bank of America Corp DE now owns 9,943 shares of the company's stock valued at $76,000 after acquiring an additional 4,473 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Sagimet Biosciences during the second quarter valued at approximately $41,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.